Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, phone calls, texts, and the like have, of course, returned. But you knew this would happen, yes? After all, this may be the high summer vacation season, but the world keeps spinning. So before you get too dizzy, please join us as we grab another cup of stimulation and dig in for a busy day. Hope your own day goes well and, as always, do keep in touch …
Celgene (CELG) raised U.S. prices by 20 percent for its Revlimid cancer drug while cutting them by 45 percent in Russia last year, NJ.com reports. The disparity in prices is not unusual, but the pricing practices could provide another line of attack for U.S. Sen. Robert Menendez (D-N.J.), who is running against former Celgene executive chairman Bob Hugin in the upcoming Senate race. Menendez has used the high cost of Revlimid in the U.S. to deflect the attacks on his own ethical problems that have been a theme of the Hugin campaign.
About the Author Reprints
My, my, what a wonderful solution to the vaccine issues in China – “blockchain” – “every step of vaccine production and distribution can be tracked on a tamper-proof ledger.” And if the initial data entered into the ledger at every step is fraudulent to begin with ……